Evidence map›Paper›PMID 41731487›Full record

ArticleDiagnostic pathology2026

Integrating histopathology and immune marker analysis for machine learning-based colorectal cancer prognostics.

Mohamed J Saadh, Tamara Nazar Saeed, Karar H Alfarttoosi, Suhas Ballal, Priya Priyadarshini Nayak, Abhayveer Singh, V Kavitha, Aziz Kubaev, Waam Mohammed Taher, Mariem Alwan and 3 more

Abstract read
In one paragraph

Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mohamed J SaadhFaculty of Pharmacy, Middle East University, Amman, 11831, Jordan.
Tamara Nazar SaeedDepartment of Medical Laboratory Technics, College of Health and Medical Technology, Alnoor University, Mosul, Iraq.
Karar H AlfarttoosiCollege of Pharmacy, Ahl Al-Bayt University, Kerbala, Iraq.
Suhas BallalDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Priya Priyadarshini NayakDepartment of Medical Oncology, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, 751003, India.
Abhayveer SinghCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab, 140401, India.
V KavithaDepartment of Chemistry, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Aziz KubaevDepartment of Maxillofacial Surgery, Samarkand State Medical University, 18 Amir Temur Street, Samarkand, 140100, Uzbekistan.
Waam Mohammed TaherCollege of Nursing, National University of Science and Technology, Dhi Qar, Iraq.
Mariem AlwanPharmacy College, Al-Farahidi University, Baghdad, Iraq.
Mahmood Jasem JawadDepartment of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.
Ali M Ali Al-NuaimiGilgamesh Ahliya University, Baghdad, Iraq.
Bagher FarhoodDepartment of Medical Physics and Radiology, Faculty of Paramedical Sciences, Kashan University of Medical Sciences, Kashan, Iran. farhood-b@kaums.ac.ir.ORCID http://orcid.org/0000-0003-2290-7220

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aims to create a machine-learning framework that integrates histopathological imaging, immune marker data, and clinical features to classify tumor types, determine histological grades, and predict survival outcomes in CRC patients. MATERIALS AND

methodsThis study analyzed 650 CRC cases, divided into training (520 cases) and testing (130 cases) subsets. Preprocessing involved quality control, color normalization, and selecting tumor regions (tumor center and invasive margins) with uniform dimensions (224 × 224 pixels). Six immune markers (CD3, CD8, CD45RO, PD-1, LAG-3, Tim-3) were selected for their relevance to CRC progression and immune response. A fine-tuned EfficientNet model was used to extract high-dimensional features from the images. These imaging features were combined with clinical data. To refine the dataset, feature selection methods such as PCA, RFE, and LASSO were applied to include only the most relevant variables. Machine learning models (XGBoost, CatBoost, Random Forest) and ensemble models were developed for tumor type and grade prediction. For survival prediction, regression models such as SVR, Random Forest Regressor, and stacking regressors were used. Model performance was evaluated using metrics such as accuracy, AUC, MSE, and the C-index.

resultsThe evaluation highlighted the value of feature selection and ensemble learning in CRC classification and survival prediction. For tumor type classification, XGBoost with RFE achieved a testing AUC of 86.15% and accuracy of 85.33%, while stacking-based models with RFE performed better, with a testing AUC of 96.73% and accuracy of 96.92%. Histological grade classification followed a similar trend, with stacking-based models achieving a testing AUC of 96.37% and accuracy of 96.92%. In survival prediction, the Stacking Regressor with RFE produced the best results, with testing MSEs of 132.87 for Disease-Free Survival (days) and 115.78 for Survival (days), along with the highest C-index of 0.84 for both tasks.

conclusionsThe proposed framework demonstrates the potential of integrating histopathological imaging, immune markers, and machine learning to improve CRC prognosis and enable personalized treatment, setting a benchmark for future computational pathology research.

Indexed as

Biomarkers, TumorColorectal NeoplasmsMachine LearningAgedBoosting Machine Learning AlgorithmsClassification AlgorithmsFemaleHumansMaleMiddle AgedNeoplasm GradingPredictive Learning ModelsPredictive Value of TestsPrognosisRandom ForestBiomarkers, TumorColorectal cancerComputational pathologyEnsemble learningHistopathological imagingImmune checkpoint markersMachine learningPrognostic modelingSurvival predictionTransfer learningTumor microenvironment

Identifiers

PMID41731487
PMCPMC13032617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.